iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 342

Identifiers

  • Canonical SMILES: 
    COC(=O)[C@H](N1[C@@H](c2ccc(Cl)cc2)C(=O)N(CCCCC(O)=O)c2ccc(I)cc2C1=O)c1ccc(Cl)cc1
  • IUPAC name: 
    5-[(3S)-3-(4-chlorophenyl)-4-[(1S)-1-(4-chlorophenyl)-2-methoxy-2-oxoethyl]-7-iodo-2,5-dioxo-3H-1,4-benzodiazepin-1-yl]pentanoic acid
  • InChi: 
    InChI=1S/C29H25Cl2IN2O6/c1-40-29(39)26(18-7-11-20(31)12-8-18)34-25(17-5-9-19(30)10-6-17)28(38)33(15-3-2-4-24(35)36)23-14-13-21(32)16-22(23)27(34)37/h5-14,16,25-26H,2-4,15H2,1H3,(H,35,36)/t25-,26+/m0/s1
  • InChiKey: 
    KXKHVDIJDBRCHO-IZZNHLLZSA-N

External links


168318233
23271220

External search

Bibliography (1)

Publication Name
Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. . Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorganic & medicinal chemistry letters. 15

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 0 0

Targets

PPI family Best activity Diseases MMoA
MDM2-Like / P53 5.55 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 694.01 g/mol
HBA 8
HBD 1
HBA + HBD 9
AlogP 6.16
TPSA 104.22
RB 10
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
16600594 15 MDM2
Q00987
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 5.55
16600594 15 MDM2
Q00987
Cellular assay Proliferation assay MCF7 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 4.60
16600594 15 MDM2
Q00987
Cellular assay Proliferation assay MDA MB321 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 4.17
Ta Structure Name Drugbank ID
0.5108 Tefinostat DB15321
0.5106 N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide DB08582
0.5042 Virginiamycin S1 DB04805
0.4922 Ombitasvir DB09296
0.4891 4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid DB08581
0.4889 Fominoben DB08968
0.4866 Bentiromide DB00522
0.4836 Proglumetacin DB13527
0.4792 Delparantag DB12955
0.4768 Oxazolam DB15491
0.4759 AGG-523 DB15460
0.4750 Benazepril DB00542
0.4740 4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide DB08344
0.4709 Daglutril DB05796
0.4703 SLV-334 DB15356